New drug candidate for spinocerebellar ataxia
Niigata, Japan - A team led by Specially Appointed Associate Professor Tomohiko Ishihara and Professor Osamu Onodera at Niigata University, along with Professor Yoshitaka Nagai at Kindai University, conducted a randomized, double-blind trial on the efficacy and safety of L-arginine in treating Spinocerebellar ataxia type 6 (SCA6).
I. Background of the Study
Spinocerebellar ataxia (SCA) is a neurodegenerative disorder affecting the cerebellum, a part of the brain responsible for coordinating movement. Symptoms include difficulties with balance, coordination, and speech (ataxia ...













